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INTRODUCTION
The incidence of intraepithelial neoplasia (IN) of the lower 
genital tract has risen during the last four decades [1]. This in-
crease is most likely due to the increased prevalence of human 
papillomavirus (HPV) infection which may induce multifocal 
precancerous epithelial lesions involving the cervix intraepi-
thelial neoplasia (CIN), vagina intraepithelial neoplasia (VAIN), 
vulva intraepithelial neoplasia (VIN), and anus intraepithelial 
neoplasia (AIN) [2]. However, not all IN of the lower genital 
tract are associated with a persistent infection of high risk 
HPV. VIN can be classified as the usual type VIN which is com-
monly associated with carcinogenic genotypes of HPV or the 
differentiated type VIN associated with vulvar dermatologic 
conditions such as lichen sclerosus [3].
Natural history and treatment options of CIN have been 
extensively studied; consequently, widely accepted guide-
lines for diagnosis, treatment and surveillance have been 
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Objective: The malignant potential of intraepithelial neoplasia of the vulva and vagina after treatment is not well defined. Our 
objective was to examine risk factors for recurrence and invasive disease. 
Methods: Four hundred sixty-four women with biopsy proven high-grade intraepithelial neoplasia of the vulva and vagina 
were identified in the electronic databases of four colposcopy clinics. Inclusion criteria were a follow-up of more than one year, 
no history of invasive cancer and no invasive cancer within the first year after initial treatment. We investigated the potential 
factors associated with recurrence and progression using a logistic regression analysis to estimate odds ratios (ORs) and 95% 
confidence intervals (CIs). 
Results: Of the 411 eligible patients, 123 patients (29.9%) recurred later than one year after initial treatment and 24 patients (5.8%) 
progressed to invasive disease. According to multivariate analyses, the risk factors associated with recurrence were multifocality 
(OR, 3.33; 95% CI, 2.02 to 5.51), immunosuppression (OR, 2.51; 95% CI, 1.09 to 5.81), excision as initial treatment (vs. laser 
evaporation; OR, 1.79; 95% CI, 1.11 to 2.91) and smoking (OR, 1.61; 95% CI, 1.02 to 2.55). Risk factors for progression to invasive 
disease were immunosuppression (OR, 4.00; 95% CI, 1.30 to 12.25), multifocality (OR, 3.05; 95% CI, 1.25 to 7.43) and smoking (OR, 
2.97; 95% CI, 1.16 to 7.60), but not treatment modality.
Conclusion: Laser evaporation combined with extensive biopsy is at least as efficacious as initial treatment of intraepithelial 
neoplasia with excision. Smoking is a risk factor for both recurrence and progression to invasive disease. Hence, smoking 
cessation should be advised and maintaining a long follow-up period due to late relapses is necessary.
Keywords: Cancer, Intraepithelial neoplasia, Laser evaporation, Vagina, Vulva
J Gynecol Oncol Vol. 24, No. 3:236-241
http://dx.doi.org/10.3802/jgo.2013.24.3.236
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
54
05
3 
| 
do
wn
lo
ad
ed
: 
13
.3
.2
01
7
Vulvovaginal intraepithelial neoplasia
J Gynecol Oncol Vol. 24, No. 3:236-241 www.ejgo.org 237
established. Despite the rise in recent years, the incidence 
rate of VIN is 2.86 per 100,000 women per year, which is ten 
times lower than that of CIN; and the incidence rates of VAIN 
and AIN are even lower [1]. As a result of these low rates, 
management recommendations for IN of the vagina, vulva 
and anus are based on relatively small prospective studies and 
retrospective series [4-6]. Although spontaneous regression 
of VIN may occur, there is consensus that IN should be treated 
due to its invasive potential as recommended by the Com-
mittee on Gynecologic Practice of the American College of 
Obstetricians and Gynecologists [6-9]. Additionally, IN seems 
to have an adverse impact on the patients’ quality of life and 
sexual functioning [10]. Nevertheless, the risk factors for the 
development of recurrent or invasive disease after treatment 
of vulvovaginal IN have not been well established. 
The aim of our multicenter retrospective cohort study was 
to determine the invasive potential, recurrence rates and 
corresponding risk factors of treated vulovaginal IN. 
MATERIALS AND METHODS
In this retrospective cohort study, patients with biopsy-prov-
en, high-grade VIN, or VAIN were identified in the electronic 
databases of four colposcopy clinics (University Hospitals of 
Berne and Zurich, Cantonal Hospitals of Bruderholz Basel and 
Frauenfeld). Patients who simultaneously had anal IN were 
also included. The following variables were extracted from 
the patients’ medical records: age at first diagnosis; unifocal or 
multifocal disease; immune status at first diagnosis (history of 
organ transplantation, human immunodeficiency virus [HIV] 
positivity, immunosuppressive medication); diagnosis of an 
invasive cancer of the vulva, vagina, or anus; type of initial and 
subsequent therapy (vulvectomy, partial vulvectomy, biopsy 
plus CO2 laser evaporation, topical medical treatment); and 
smoking habits (more than 10 cigarettes per day). Follow-up 
visits were usually scheduled every six months for the first five 
years, and then on an annual basis in subsequent years.
Only patients with a follow-up of twelve months or longer 
after initial diagnosis were included in the analysis. If a patient 
had both excision and biopsy combined with laser evapora-
tion during the first year, laser evaporation was considered 
the initial treatment since it is the more comprehensive type 
of therapy. It was the policy of all colposcopy clinics involved 
in our study to re-excise involved margins. Exclusion criteria 
were a history of either invasive vulvar, vaginal, anal or cervical 
cancer, but not a history of CIN. Patients with the diagnosis 
of invasive cancer within one year from initial diagnosis of 
IN were also excluded in order to minimize falsely detecting 
preexisting invasive disease due to incorrect initial diagnosis. 
Low grade IN (formerly VIN I) was not considered an inclusion 
criterion since it had been omitted from the classification 
system for VIN developed by the International Society for the 
Study of Vulvovaginal Diseases (ISSVD) in 2005 [3]. 
Recurrence was defined as biopsy-proven IN one year and 
later after initial treatment. We applied this definition in order 
to exclude patients with inappropriate and/or insufficient ini-
tial treatment requiring immediate retreatment at the centers. 
The study’s primary endpoints were progression to invasive 
disease and biopsy-proven recurrence. 
Both univariate and multivariate data analyses were con-
ducted in IBM SPSS ver. 19.0 (IBM Co., Armonk, NY, USA). The 
Kaplan-Meier estimator was used to estimate the survival func-
tion from data on recurrence of IN and progression to cancer. 
Multinomial logistic regression models (stepwise backward) 
were used to control for potential confounding factors (age at 
initial diagnosis, immune status, focality, grade [grade 2 vs. 3], 
type of treatment and smoking behavior [>10 cigarettes per 
day]) on discrete outcomes. Pearson’s chi squared tests were 
used to detect differences in non-parametric variables. All tests 
were performed at a significance level of α=0.05 and confi-
dence intervals were computed at a level of 95%. The study 
protocol was reviewed and approved by the local Institutional 
Review Boards (StV Nr. 08/2006) and written informed consent 
for review of patient charts was obtained.
RESULTS
Of 464 patients identified from 1977 to 2011, 411 patients 
(88.6%) had a follow-up longer than one year and were included 
in the analysis. Mean age at diagnosis was 46 years (±14; range, 
17 to 90 years). With regard to the type of IN, 381 patients 
(92.7%) presented with high-grade vulvar and 30 patients (7.3%) 
with vaginal anal IN. Patient and treatment characteristics are 
presented in Table 1. Among the immunosuppressed patients, 
19 patients (4.6%) were HIV positive, 9 patients (2.2%) were 
recipients of organ transplantation and were taking immune-
suppressing medication, and 5 patients (1.2%) were under 
long-term steroid medication. 
Initial treatment during the first year after diagnosis was sur-
gical biopsy combined with CO2 laser evaporation in 270 pa-
tients (65.7%), surgical excision alone in 114 patients (27.7%), 
and vulvectomy in 19 patients (4.6%). Laser evaporation was 
used consistently throughout the study period, although a 
peak was noted in the early part of the decade 2000. The use 
of excisions peaked in the middle of the 1990s, yet continued 
to be used on a relatively frequent basis in more recent years. 
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For eight patients (1.9%), the initial treatment within the first 
12 months was photodynamic therapy or local drug applica-
tion such as imiquimod. Mean follow-up time was 85 months 
(±56; range, 13 to 389 months).
Recurrence occurred later than one year after initial diagno-
sis in 123 patients (29.9%), and 24 patients (5.8%) progressed 
to invasive disease. One of 30 women (3.3%) with an initial 
diagnosis of VAIN progressed to invasive cancer, and 23 of 377 
patients (6.1%) with VIN progressed (p=0.999). The types of 
cancer detected during follow-up were vulvar (16), vaginal (4), 
and perianal (4). In the 241 patients with a follow-up longer 
than five years, 34.9% (84) were still experiencing recurrences. 
Based on multivariate analyses, risk factors associated with 
recurrence included immunosuppression, multifocal disease, 
excision as initial treatment and smoking (Table 2). Further-
more, risk factors for progression to invasive disease were 
Table 1. Associations of patient characteristics with recurrence and progression of the disease more than 12 months after initial diagnosis of 
intraepithelial neoplasia
Characteristic No. (%)
Recurrence Progression to invasive cancer   
No. (%)  p-value No. (%) p-value
Total 411 123 (29.9) - 24 (5.8) -
Grade of intraepithelial neoplasia
    2 86 (20.9) 24 (27.9) 0.646 6 (7.0) 0.614
    3 325 (79.1) 99 (30.5) 18 (5.5)
Focality
    Unifocal 308 (74.9) 67 (21.8) <0.001 11 (3.6) 0.001
    Multifocal 103 (25.1) 56 (54.4) 13 (12.6)
Immunosuppression
    None 382 (92.9) 108 (28.3) 0.008 19 (5.0) 0.007
    Present 29 (7.1) 15 (51.7) 5 (17.2)
Smoking (>10 cigarettes/day)
    No 238 (57.9) 59 (24.8) 0.008 8 (3.4) 0.012
    Yes 173 (42.1) 64 (37.0) 16 (9.2)
Initial treatment
   Surgery 128 (31.1) 51 (39.8) 0.001 11* (8.6) 0.059
   Laser and biopsy 275 (66.9) 66 (24.0) 11* (4.0)
*Two patients who progressed to invasive cancer underwent medical treatment as initial treatment. They both had a recurrence prior to 
progression which was treated by laser surgery in one case and surgical excision in the other.
Table 2. Multivariate regression analysis for the development of recurrence or invasive disease more than 12 months after initial diagnosis of 
intraepithelial neoplasia
Variable
Recurrence Progression to invasive cancer
OR 95% CI  p-value OR 95% CI p-value
Immunosuppression:  
  present vs. not present
2.51 1.09-5.81 0.031 4.00 1.30-12.25 0.015
Focality: 
  multifocal vs. unifocal
3.33 2.02-5.51 <0.001 3.05 1.25-7.43 0.014
Smoking (>10 cigarettes /day) 
  vs. not smoking
1.61 1.02-2.55 0.043 2.97 1.16-7.60 0.023
Initial treatment: 
  surgical excision vs. laser surgery
1.79 1.11-2.91 0.017 2.09 0.81-5.37 0.126
Grade of intraepithelial neoplasia: 
  3 vs. 2
0.96 0.54-1.71 0.889 0.58 0.20-1.74 0.333
Age at diagnosis 0.99 0.97-1.01 0.296 0.99 0.96-1.03 0.742
CI, confidence interval; OR, odds ratio. 
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immu no suppression, multifocal disease and smoking. The 
survival analysis for recurrence of IN by initial treatment modal-
ity (excision versus biopsy with laser evaporation) indicated a 
more favorable outcome for those patients treated with laser 
evaporation (Fig. 1). 
The mean time from first diagnosis to invasive disease was 
82 months (±74; range, 13 to 290 months). However, as 
shown in Fig. 2, two peaks were observed: the first peak was 
within the second and third years after initial treatment and 
the second peak was within the seventh and eighth years. In 
46% (11/24) of patients with progression to invasive disease, 
cancer was diagnosed within the first three years, whereas 
disease progression occurred five years or later after initial 
diagnosis in 54% (13/24). Twenty-two of the 24 patients 
developing invasive cancer had a second treatment for recur-
ring IN before cancer diagnosis. Cancer stages were as follows: 
14 patients had microinvasive vulvar cancer (pT1a), three 
patients had pT1b pN0 vulvar cancer, three patients had pT2 
pN0 vulvar cancer, three patients had T1 pN0 vaginal cancer 
and one patient had pT1, pN1 vaginal cancer. The patient with 
node positive vaginal cancer died of disease at age forty.
DISCUSSION
Treatment of vulvovaginal IN is associated with high recur-
rence rates. A systematic review of 3,322 published patients 
with VIN III showed a recurrence rate of 19% after vulvectomy, 
18% after partial vulvectomy, 22% after local excision, and 
23% after laser evaporation [6]. The higher recurrence rate 
observed in our study (29.9%) may be due to the substantially 
longer mean follow-up time of 85 months compared to 39 
months in the above-mentioned review. In addition, our 
results are consistent with the results of a recently published 
prospective study on VIN recurrence rates [4]. We do not think 
that our higher recurrence rate is overestimated since our def-
inition of recurrence was histologically proven disease more 
than 12 months after initial diagnosis. Hence, an incomplete 
excision followed by re-excision within a year was counted 
as one treatment. Additionally, 34.9% of those patients with 
long follow-up periods had recurrences at least five years 
after initial treatment, which highlights the importance of 
maintaining a long follow-up period for this disease.
Other researchers have found significantly lower recurrence 
rates if the surgical margins were free of IN (17%) than with 
involved margins (47%) [6,11]. Due to the long retrospective 
time frame of our study, we were not able to re-examine the 
excised tissue specimen. Initial treatment subsumed all treat-
ments within the first year after initial diagnosis. Therefore, we 
had patients who had local excision as first treatment followed 
by laser evaporation due to involved margins. In this case, initial 
treatment was considered to be laser evaporation since both 
treatments were within the first year. We chose this definition 
since many patients had some sort of incomplete treatment 
prior to referral to our centers and they were immediately 
retreated until free margins were achieved.
Herod et al. [12] reported a higher recurrence rate in 133 
women with high-grade VIN following laser evaporation than 
after local excision (75% vs. 40%). Moreover, the systematic re-
view by van Seters et al. [6] did not find a significant difference 
between these two treatment modalities. In contrast, our study 
showed superior treatment results for laser evaporation with a 
24% recurrence rate compared to 39.8% for surgical excision 
(p=0.001). In multivariate analyses, this result was confirmed. 
Again, we believe that the longer follow-up time in our study 
might explain these differences. We consider this result im-
portant since normal morphology are often better preserved 
using laser treatment than using surgical excision. Since this is 
Fig. 1. Recurrence-free survival analysis of vulvovaginal intraepithelial 
neoplasia by initial treatment modality of either laser evaporation or 
surgical excision.
Fig. 2. Years to invasive disease after first treatment for intraepithelial 
neoplasia (n=24).
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a retrospective cohort study, treatment results may have been 
influenced by selection bias. Selection bias would imply that 
more severe, larger or multifocal IN lesions would have been 
treated by excision resulting in a higher recurrence rate of this 
treatment modality. However, in practice, larger or multifocal 
lesions are more likely to be treated by biopsy and laser eva-
po ration in order to maintain normal vulvar morphology.
Besides initial treatment, this analysis identified other inde-
pendent risk factors for recurrence including cigarette smok-
ing, immunosuppression and multifocality. Multifocal disease 
has been described as a risk factor for recurrence in other 
studies [8,13-15]. Multifocal IN is known to be HPV-related, 
whereas surgical treatment of the visible lesion may not clear 
the HPV-infection [16,17]. Accordingly, persistence of HPV 
infection has been described as a risk factor for recurrence of 
VIN [13]. Immunosuppression is a known risk factor for both 
occurrence and recurrence of IN of the lower anogenital tract 
[18-21]. 
Cigarette smoking is among the most well established HPV 
cofactors in the etiology of cervical and vulvar cancer [22]. The 
biological mechanisms whereby cigarette smoking increases 
cervical and vulvar cancer risk remain largely undetermined. 
One possibility is that smoking enhances immunosuppression 
since constituents of cigarette smoke and their metabolites 
are present in the cervical mucus and depress populations 
of cervical Langerhans cells and T lymphocytes [23-25]. The 
risk associated with smoking is modified by genetic variation 
in Interleukin 2 which propagates a T lymphocyte-mediated 
immune response to HPV and tumor antigens [26]. On the 
other hand, smoking cessation has been shown to have an 
effect on colposcopic lesion size of CIN grade 1 or less [27]. 
However, to the best of our knowledge, the present study 
is the first to demonstrate the risk of smoking on recurrence 
and progression of VIN and VAIN using a multivariate analysis. 
Smokers had a 1.6 and 3 times higher risk of recurrence and 
progression to invasive cancer, respectively. 
Progression to cancer at least one year after initial treatment 
occurred in 5.8% of our treated patients. This is consistent 
with findings from Jones et al. [8] who observed a progression 
rate of 3.8% in 342 treated patients, with half of the women 
followed for more than five years. In a population-based 
analysis of the Cancer Registry of Norway, 3.4% of 468 women 
with VIN developed invasive squamous cell carcinoma of the 
vulva later than seven months after initial diagnosis of VIN [28]. 
In this study, it is not clear if invasive recurrences in the vaginal 
or anal skin did not occur or were not considered.
Fifty-four percent of invasive cancers in our study were diag-
nosed more than five years after initial diagnosis of IN. Jones 
et al. [8] proposed the term “treatment failure” for invasive 
cancer which develops within seven years following initial 
diagnosis of IN and “new field cancers” for cancers occurring 
later. As in our series, about half of invasive cancers were 
considered to be “new field cancers” in the latter study. Inde-
pendent risk factors for the development of an invasive cancer 
of the vulva or vagina were multifocal IN, immunosuppression 
and smoking. Twenty-two of the 24 patients who experienced 
invasive cancer had at least one treatment for recurring IN 
prior to cancer diagnosis. Hence, it seems plausible that risk 
factors for recurrence and progression to invasive disease 
overlap. Additionally, immunosuppression and smoking may 
facilitate the development of “new field cancers” as discussed 
earlier.
The results of this study are limited by the retrospective 
design. However, it is the largest dataset of patients with IN 
of the vulva and vagina on which a multivariate analysis was 
performed and the follow-up period is long. Since 35% of re-
lapses occurred after five years, maintaining a long follow-up 
period is necessary. Unfortunately, information about whether 
patients stopped or continued to smoke after initial diagnosis 
of IN was not available. However, since our results showed 
that cigarette smoking increased the risk of recurrence as 
well as progression to invasive disease, counseling women 
with genital IN to stop smoking seems advisable. Smoking 
cessation counseling is feasible in this patient population, and 
results on the effect of smoking cessation on recurrence and 
progression rate are eagerly awaited [29]. 
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